Micah Blackmon, MD
Urology · Newnan, GANPI 1588876411
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.9%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Axonics, Inc. at 38.8% of the total.
Across 236 payments — averaging $65.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$6K
- Procept Biorobotics Corporation$3K
- Boston Scientific$2K
- Neotract Inc.$2K
- Coloplast$1K
- Teleflex LLC$275
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$4233%
- Travel & lodging$7,19547%
- Food & beverage$7,71550%
- Education$1281%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 78 | $5,997 |
| Procept Biorobotics Corporation | 24 | $2,834 |
| Boston Scientific | 22 | $1,734 |
| Neotract Inc. | 13 | $1,658 |
| Coloplast | 15 | $1,314 |
| Teleflex LLC | 7 | $275 |
| Palette Life Sciences, Inc. | 5 | $270 |
| Sumitomo Pharma America, Inc. | 11 | $217 |
| AbbVie | 8 | $195 |
| Astellas Pharma US Inc | 6 | $109 |
| Laborie Medical Technologies Corp. | 4 | $93 |
| Medtronic(2 entities) | 6 | $79 |
| Olympus America Inc. | 5 | $76 |
| Ambu Inc. | 3 | $58 |
| Urogen Pharma, Inc. | 2 | $54 |
| Endo USA, Inc. | 2 | $45 |
| Antares Pharma, Inc. | 1 | $44 |
| Urovant Sciences Inc | 2 | $41 |
| 180 Medical, Inc. | 2 | $38 |
| Ferring Pharmaceuticals Inc. | 2 | $38 |
| Rochester Medical Corporation | 2 | $34 |
| Johnson & Johnson | 1 | $33 |
| Tolmar, Inc. | 1 | $27 |
| Novartis | 1 | $26 |
| Endo Pharmaceuticals Inc. | 1 | $24 |
| Merck | 1 | $22 |
| Baxter Healthcare | 1 | $21 |
| Calyxo, Inc. | 1 | $20 |
| Myovant Sciences Inc. | 1 | $20 |
| Intuitive Surgical | 1 | $18 |
| Sagent Pharmaceuticals | 1 | $18 |
| Travere Therapeutics, Inc. | 5 | $16 |
| Photocure Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$2,994
- AquaBeam Robotic System$2,112
- UroLift$1,353
- TITAN$1,120
- Bulkamid$1,073
- SPACEOAR$1,054
- Axonics r-SNM System$960
- AQUABEAM SYSTEM$145
- AMS 700$106
How this compares
$15,461 in reported general payments places this provider in the 85th percentile of 369 urology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 111 | $80,584 |
| MyrbetriqMirabegron | 69 | $57,321 |
| Tamsulosin Hcl | 889 | $10,077 |
| Finasteride | 244 | $2,936 |
| Testosterone Cypionate | 39 | $1,788 |
| Estradiol | 29 | $1,422 |
| Dutasteride | 47 | $1,271 |
| NitrofurantoinNitrofurantoin Macrocrystal | 33 | $1,072 |
| Terazosin Hcl | 30 | $766 |
| Trospium Chloride | 24 | $580 |
| Doxazosin Mesylate | 40 | $504 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 83 | $380 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 17 | $345 |
| Doxycycline Hyclate | 11 | $276 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 18 | $271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $217 | $80,584111 claims |
| Astellas Pharma US IncMyrbetriq | $109 | $57,32169 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 369 urology providers in Georgia.
Other urology in Newnan
- Vahan KassabianRoswell$1.6M
- Lewis KritemanRoswell$864K
- Daniel CanterDecatur$329K
- Tariq HakkyAtlanta$140K
- Sherita KingAugusta$108K
- Brittani Barrett-HarlowFayetteville$100K
- James BennettAtlanta$93K
- Anthony BarnesAtlanta$89K
- Scott MillerRoswell$85K
- Matthew SandAtlanta$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.